Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G A Burkhart

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|June 1, 1997
Race and angioedemaG A Burkhart
Annals of Internal Medicine|September 1, 1995
Aspirin and colorectal cancerG A Burkhart
JAMA|February 3, 1999
Time for action on drug safetyG A Burkhart
The American Journal of Cardiology|January 15, 1995
The risk of life-threatening cardiovascular events with terfenadineG A Burkhart, J Freiman
Clinical Pharmacology and Therapeutics|January 1, 1997
Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycinG A Burkhart, M J Sevka, R Temple, et al.
Clinical Pharmacology and Therapeutics|June 19, 1998
Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressantsS R Weiss, B H McFarland, G A Burkhart, et al.
British Journal of Industrial Medicine|April 1, 1992
Effects of exposure to carbon disulphide on low density lipoprotein cholesterol concentration and diastolic blood pressureG M Egeland, G A Burkhart, T M Schnorr, et al.
The New England Journal of Medicine|May 1, 1997
High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosisS C FitzSimmons, G A Burkhart, D Borowitz, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|June 1, 1997
Race and angioedemaG A Burkhart
Annals of Internal Medicine|September 1, 1995
Aspirin and colorectal cancerG A Burkhart
JAMA|February 3, 1999
Time for action on drug safetyG A Burkhart
The American Journal of Cardiology|January 15, 1995
The risk of life-threatening cardiovascular events with terfenadineG A Burkhart, J Freiman
Clinical Pharmacology and Therapeutics|January 1, 1997
Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycinG A Burkhart, M J Sevka, R Temple, et al.
Clinical Pharmacology and Therapeutics|June 19, 1998
Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressantsS R Weiss, B H McFarland, G A Burkhart, et al.
British Journal of Industrial Medicine|April 1, 1992
Effects of exposure to carbon disulphide on low density lipoprotein cholesterol concentration and diastolic blood pressureG M Egeland, G A Burkhart, T M Schnorr, et al.
The New England Journal of Medicine|May 1, 1997
High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosisS C FitzSimmons, G A Burkhart, D Borowitz, et al.
Pageof 1